Loading…
Loading…
Acute myeloid leukemia is a cancer of immature myeloid cells that builds up in the bone marrow and stops normal blood production.
Quick Answer
Acute myeloid leukemia is a cancer of immature myeloid cells that builds up in the bone marrow and stops normal blood production. Dr. Sachita Baniya (NMC 20158, 8+ years of clinical experience in haematology and haemato-oncology) evaluates acute myeloid leukemia (aml) at Kathmandu Neurology Clinic & Cognitive Center, 117 Lal Durbar Marg, Kathmandu, Bagmati Province 44600, Nepal — evidence-based, medically reviewed.
AML develops when myeloid stem cells acquire genetic changes that block normal maturation. Immature blasts accumulate in the marrow, causing anaemia, infection and bleeding. It can arise de novo or after prior chemotherapy or a myelodysplastic syndrome. Diagnosis and genetic subtype guide treatment intensity and transplant decisions.
Diagnosis requires bone marrow aspiration and biopsy showing increased blasts, supported by flow cytometry, cytogenetics, FISH and molecular testing. Blood counts, coagulation and organ function are assessed before treatment.
Treatment is risk-adapted. Fit patients usually receive intensive induction chemotherapy, then consolidation with chemotherapy or allogeneic transplant. Unfit patients may receive lower-intensity therapy with hypomethylating agents and venetoclax. Targeted drugs are chosen by mutation, and supportive care is continuous.
Management is individualized and discussed with benefits, limitations, and follow-up.
There is no proven way to prevent most AML. Avoiding unnecessary radiation and benzene exposure, and monitoring people with inherited marrow failure or prior myelodysplasia, are reasonable measures.
Red flags — seek urgent care
AML can be cured in a proportion of patients, particularly younger adults who achieve remission and proceed to appropriate consolidation or transplant. Outcomes vary widely with genetic subtype, age and fitness, so the treating team discusses prognosis for the individual case rather than giving a single figure.
Induction is the first phase of treatment, aiming to clear leukemia cells from the marrow and restore normal blood production. It usually requires hospital admission and close support with transfusion, infection prevention and monitoring.
Cytogenetics and molecular tests identify subtypes with different risk and different treatment options. For example, FLT3, IDH1/2, NPM1 and TP53 results can change both prognosis and drug selection.
MRD refers to leukemia cells that remain below the level visible on microscopy. It is measured by flow cytometry or molecular methods and helps judge how deep the response is and whether transplant should be considered.
Allogeneic transplant is considered for selected high-risk or relapsed AML, and sometimes for intermediate-risk disease with persistent MRD. Eligibility depends on age, organ function, donor availability and patient preference.
Supportive care includes red cell and platelet transfusion, infection prevention and prompt treatment of febrile neutropenia, growth factors where appropriate, nausea control, nutrition and careful monitoring of organ function.
Yes. Older or less fit patients may receive lower-intensity regimens, including hypomethylating agents with venetoclax or targeted therapy. The aim may be remission, disease control or improved quality of life, depending on the individual.
Ask about the genetic subtype, risk group, treatment intent, expected admission time, supportive-care needs, transplant eligibility and the follow-up plan. Written summaries help families process a large amount of information.
Diagnosis, risk stratification and treatment planning for acute and chronic leukemias.
Donor stem cell transplant for selected high-risk blood cancers and marrow failure.
Diagnostic bone marrow sampling for cytopenias, suspected blood cancer and treatment monitoring.
Acute lymphoblastic leukemia is a cancer of immature lymphoid cells that accumulates in the marrow and can involve the central nervous system.
Chronic myeloid leukemia is a myeloproliferative cancer driven by the BCR-ABL1 fusion gene and treated with tyrosine kinase inhibitors.
Myelodysplastic syndromes are clonal marrow disorders causing low blood counts and a variable risk of progression to leukemia.
Haematology
Blood Cancer Symptoms: When to See a Haematologist
Unexplained bruising, persistent fatigue, swollen lymph nodes or repeated infections can be early signs of a blood disorder. Here is when to seek a haematology opinion.
Haematology
AML Diagnosis Explained: From Blood Count to Genetic Risk
How acute myeloid leukemia is diagnosed, why bone marrow and genetic testing matter, and what the results mean for treatment.
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.
Doctor — medically reviewed
Dr. Sachita Baniya
Consultant Haemato-Oncologist & Clinical Hematologist • MBBS, FCPS (Clinical Haematology) • NMC 20158
This condition guide was medically reviewed by Dr. Sachita Baniya.
On this site
Article information
Emergency
For sudden neurologic change, thunderclap headache, or seizure >5 min, seek emergency services now.